Generis has announced two out of the three leading COVID-19 vaccine initiatives in Operation Warp Speed are using the CARA Life Science Platform for Regulatory.
The CARA Life Sciences Platform, provided by Generis, is helping these Life Science companies to reduce their development and submission cycles while focusing on oversight and compliance with stringent health regulations.
“We estimate that around 262,500 users of our CARA Life Sciences Platform are currently working on COVID-19 vaccines or treatments globally,” James Kelleher, CEO, Generis said. “That tangible impact on the future of our societies, economies, and personal wellbeing is something that Generis is extremely proud of. We know and appreciate that every effort from our developers, consulting, support and training teams, as well as industry leaders, will have a profound impact in saving and improving human life.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!
The CARA Life Sciences Platform manages regulated business processes, managing content and data across the core functional areas of Life Science companies. Adoption of this platform has driven process efficiency improvements of up to 450%*, greatly reducing time-to-market for regulated products.